CDK inhibitors: cell cycle regulators and beyond.

By A. Besson, S. Dowdy, J. M. Roberts. Developmental Cell, 2008

1,154 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cyclin D1, Cancer Progression and Opportunities in Cancer Treatment (2016, background): “Due to their biological significance, CDK activity is stringently regulated by the following mechanisms: the levels of cyclin partners, phosphorylation status, and the abundance of CDK inhibitory proteins, such as the INK4 family (p16, p15, p18, and p19) and the CIP and KIP families (p21, p27, and p”
Cdks, cyclins and CKIs: roles beyond cell cycle regulation (2013, background): “Besides transcription, Cip/Kip proteins display essential roles in the regulation of apoptosis and actin cytoskeletal dynamics (Besson et al., 2008), topics that are not covered here owing to space constraints.”
Cyclin D as a therapeutic target in cancer (2011, background): “The synthesis of individual cyclins, and consequent cyclin-dependent kinase (CDK) activation at specific cell cycle stages, coordinates the sequential completion of DNA replication and cell divisio”
p21 in cancer: intricate networks and multiple activities (2009, background): “Although this activity is shared by other CDK inhibitors such as p27 and p57, biochemical and genetic evidence suggest that they have distinct roles in tumorigenesi”